TY  - JOUR
AU  - Ruiz-Villaverde, Ricardo
AU  - Chinchay, Fiorella Vasquez
AU  - Rodriguez-Fernandez-Freire, Lourdes
AU  - Armario-Hita, Jose C
AU  - Pérez-Gil, Amalia
AU  - Galán-Gutiérrez, Manuel
PY  - 2022
DO  - 10.1111/dth.15835
UR  - http://hdl.handle.net/10668/19942
T2  - Dermatologic therapy
AB  - Psoriasis (PSO) is an inflammatory disease that emerges as a dysregulation of the interleukin 23 (IL23)/Th17 axis. There are many biologic alternatives to treat PSO that are administered monthly, every 2 months and every 3 months. Guselkumab (GUS) is...
LA  - en
KW  - guselkumab
KW  - optimization
KW  - psoriasis
KW  - switching
KW  - Adult
KW  - Humans
KW  - Ustekinumab
KW  - Retrospective Studies
KW  - Severity of Illness Index
KW  - Double-Blind Method
KW  - Treatment Outcome
KW  - Psoriasis
KW  - Biological Products
TI  - Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab.
TY  - research article
VL  - 35
ER  -